COMMUNIQUÉS West-GlobeNewswire

Metabo Drops Examined: Is It Legit for Weight Loss? Safety Checks and Consumer Analysis 2026
13/01/2026
New York, NY, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Consumer interest in supplement legitimacy continues to rise as transparency becomes a deciding factor in purchasing decisions. Searches that include phrases such as “Is [...]
SPINEWAY : 2025 revenue of €12.4 million, with an acceleration of sales in Q4 2025 (+34%)
13/01/2026
Ecully, January 13, 2026 – 6:30 p.m. SPINEWAY 2025 revenue of €12.4 million, with an acceleration of sales in Q4 2025 (+34%) In thousands of euros 2025 2024 Change as a % H1 revenue 5,573 6,535 -15% H2 revenue 6,857 5, [...]
SPINEWAY : Chiffre d’affaires annuel 2025 de 12,4 ME avec une accélération des ventes au T4 2025 (+34%)
13/01/2026
Ecully, le 13 janvier 2026 – 18h30 SPINEWAY Chiffre d’affaires annuel 2025 de 12,4 M€ avec une accélération des ventes au T4 2025 (+34%) En milliers d’euros 2025 2024 Variation en % CA 1 er semestre 5 573 6 535 - 15% CA [...]
U.S. FDA grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia
13/01/2026
Breakthrough Therapy Designation granted for investigational therapy IPN60340 in combination with venetoclax and azacitidine in first line unfit acute myeloid leukemia PARIS, FRANCE, 13 JANUARY 2026 - Ipsen (Euronext: [...]
Metabo Drops 2026: Is It Legit? Ingredients, Safety Facts, and Consumer Analysis
13/01/2026
Consumer searches for supplement legitimacy increased 26% year-over-year as transparency becomes central purchasing criterion — industry analysis examines what drives "Is It Legit?" search behavior and how liquid [...]
Wegovy Pill vs Wegovy Shot: Oral vs Injectable Semaglutide Differences — 2026 FDA Launch Analysis via Ro.co
13/01/2026
Comprehensive comparison of daily oral vs weekly injectable Wegovy following Novo Nordisk's January 2026 FDA approval of the first oral GLP-1 for chronic weight management — Ro.co telehealth access pathway examination [...]
Best Hair Regrowth Formula 2026 (BioGrow RX): Consumer Report Compares Biotin Supplements to Topical Treatments
13/01/2026
2026 Hair Wellness Report: Biotin Complex vs Topical Serums – Format Selection, Label Transparency, and Daily Routine Fit NORTH LARGO, FL, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational [...]
Best Testosterone Replacement Therapy (TRT) 2026: Taurus Meds Consumer Analysis Examines Online TRT Access and At-Home Testosterone Treatment Options
13/01/2026
Consumer Report Details Low Testosterone Treatment Costs, LabCorp and Quest Lab Testing, Licensed Provider Access, and What Men Need to Know Before Starting Online TRT WILMINGTON, DE, Jan. 12, 2026 (GLOBE NEWSWIRE) -- [...]
Wegovy Pill Legitimacy Examined: 2026 Consumer Analysis Investigates Ro's Oral GLP-1 Access Pathway and No-Insurance Cash-Pay Options
13/01/2026
As Novo Nordisk launches first FDA-approved oral weight loss medication, independent examination evaluates Ro's direct-to-patient distribution model, pricing transparency, and telehealth access structure for patients [...]
Best Electrolyte Supplement Analysis 2026: Seaonic Challenges Top Hydration Packets With Ocean-Sourced Minerals
13/01/2026
A deep-dive into what's driving the shift toward seawater-derived electrolytes—and how Seaonic's published disclosures compare with common verification criteria DENVER, CO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disclaimer: [...]
Option Care Health Announces Preliminary Fourth Quarter & Full Year 2025 Financial Results and Preliminary Financial Guidance for Full Year 2026
12/01/2026
BANNOCKBURN, Ill., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion [...]
Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer
12/01/2026
WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for [...]
CareMed Has Been Selected as a National Specialty Pharmacy Provider for MYQORZO™ (aficamten)
12/01/2026
NEW HYDE PARK, N.Y., Jan. 12, 2026 (GLOBE NEWSWIRE) -- CareMed ® , an independent specialty pharmacy, has been selected as a pharmacy partner by Cytokinetics for MYQORZO™ ( aficamten ), indicated for the treatment of [...]
IBA – TRANSPARENCY NOTIFICATION
12/01/2026
(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings) Louvain-la-Neuve, Belgium, January 12, 2026 10:30 PM Summary of the notification IBA (Ion Beam Applications), the world’s leading [...]
IBA SA – NOTIFICATION TRANSPARENCE
12/01/2026
(article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes) Louvain-la-Neuve, Belgique, le 12 janvier 2026, 22:30 Résumé de la notification IBA (Ion Beam Applications SA), le [...]
Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia
12/01/2026
- SGT-212 has received FDA Fast Track, Rare Pediatric Disease and Orphan Drug designations - - Dosing of the first participant in the Phase 1b FALCON trial has been completed, with initial data expected in H2 2026, [...]
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
12/01/2026
NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that it has granted to Ellen Rose, the new Senior Vice President, Corporate [...]
Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2025 and Provides Revenue Guidance for the First Quarter of 2026
12/01/2026
INSIDE INFORMATION REGULATED INFORMATION Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2025 and Provides Revenue Guidance for the First Quarter of 2026 Strong Start in First Full Quarter of U [...]
Nyxoah Annonce ses Résultats Préliminaires pour le Quatrième Trimestre et l'Ensemble de l'Exercice 2025 et Communique des Prévisions de Chiffre d'Affaires pour le Premier Trimestre 2026
12/01/2026
INFORMATIONS PRIVILÉGIÉES INFORMATIONS RÉGLEMENTÉES Nyxoah Annonce ses Résultats Préliminaires pour le Quatrième Trimestre et l'Ensemble de l'Exercice 2025 et Communique des Prévisions de Chiffre d'Affaires pour le [...]

Pages